B K Moore1, E Anyalechi1, M van der Walt2, S Smith1, L Erasmus3, J Lancaster2, S Morris1, N Ndjeka4, J Ershova1, N Ismail5, D Burton1, H Menzies1. 1. Centers for Disease Control and Prevention, Atlanta, Georgia, USA. 2. South African Medical Research Council, Cape Town, South Africa. 3. National Institute for Communicable Diseases, National Health Laboratory Service, Johannesburg, South Africa. 4. South Africa National Department of Health, Pretoria, South Africa. 5. National Institute for Communicable Diseases, National Health Laboratory Service, Johannesburg, University of Pretoria, Pretoria, South Africa.
Abstract
OBJECTIVE: To describe the demographic and clinical characteristics of children and adolescents diagnosed with resistance to any anti-tuberculosis drug (drug-resistant tuberculosis; DR-TB) in South Africa. DESIGN: We retrospectively reviewed medical records of all children (<13 years) and adolescents (13 to <18 years) with DR-TB at specialty hospitals in four South African provinces from 2005 to 2010. RESULTS: During the review period, 774 children and adolescents (median age 11.3 years) were diagnosed with DR-TB at selected facilities. A high proportion of patients had a history of previous TB treatment (285/631; 45.2%), human immunodeficiency virus (HIV) infection (375/685; 54.7%), contact with a TB case (347/454; 76.4%), and smear-positive (443/729; 60.8%), cavitary (253/680, 38.7%) disease. Eighty-two per cent of patients with HIV infection received antiretroviral therapy. Of 626 patients diagnosed with multidrug-resistant TB (MDR-TB), 561 (89.6%) received a regimen consistent with national guidelines; the median length of treatment was 22 months (IQR 16-25). Among 400 patients with any DR-TB and a known outcome, 20.3% died during treatment. CONCLUSION: Pediatric DR-TB in these provinces is characterized by complex clinical features at diagnosis, with one in five children dying during treatment. History of previous treatment and contact with a TB patient indicate opportunities for earlier diagnosis and treatment to improve outcomes.
OBJECTIVE: To describe the demographic and clinical characteristics of children and adolescents diagnosed with resistance to any anti-tuberculosis drug (drug-resistant tuberculosis; DR-TB) in South Africa. DESIGN: We retrospectively reviewed medical records of all children (<13 years) and adolescents (13 to <18 years) with DR-TB at specialty hospitals in four South African provinces from 2005 to 2010. RESULTS: During the review period, 774 children and adolescents (median age 11.3 years) were diagnosed with DR-TB at selected facilities. A high proportion of patients had a history of previous TB treatment (285/631; 45.2%), humanimmunodeficiency virus (HIV) infection (375/685; 54.7%), contact with a TB case (347/454; 76.4%), and smear-positive (443/729; 60.8%), cavitary (253/680, 38.7%) disease. Eighty-two per cent of patients with HIV infection received antiretroviral therapy. Of 626 patients diagnosed with multidrug-resistant TB (MDR-TB), 561 (89.6%) received a regimen consistent with national guidelines; the median length of treatment was 22 months (IQR 16-25). Among 400 patients with any DR-TB and a known outcome, 20.3% died during treatment. CONCLUSION: Pediatric DR-TB in these provinces is characterized by complex clinical features at diagnosis, with one in five children dying during treatment. History of previous treatment and contact with a TBpatient indicate opportunities for earlier diagnosis and treatment to improve outcomes.
Authors: James A Seddon; Anneke C Hesseling; Marianne Willemse; Peter R Donald; H Simon Schaaf Journal: Clin Infect Dis Date: 2011-11-03 Impact factor: 9.079
Authors: Helen E Jenkins; Arielle W Tolman; Courtney M Yuen; Jonathan B Parr; Salmaan Keshavjee; Carlos M Pérez-Vélez; Marcello Pagano; Mercedes C Becerra; Ted Cohen Journal: Lancet Date: 2014-03-24 Impact factor: 79.321
Authors: Ben J Marais; Robert P Gie; H Simon Schaaf; Nulda Beyers; Peter R Donald; Jeff R Starke Journal: Am J Respir Crit Care Med Date: 2006-02-16 Impact factor: 21.405
Authors: Evan W Orenstein; Sanjay Basu; N Sarita Shah; Jason R Andrews; Gerald H Friedland; Anthony P Moll; Neel R Gandhi; Alison P Galvani Journal: Lancet Infect Dis Date: 2009-03 Impact factor: 25.071
Authors: E Marais; C K Mlambo; J J Lewis; N Rastogi; T Zozio; M P Grobusch; A Duse; T Victor; R W Warren Journal: Infection Date: 2013-12-21 Impact factor: 3.553
Authors: H Simon Schaaf; Ben J Marais; Andrew Whitelaw; Anneke C Hesseling; Brian Eley; Gregory D Hussey; Peter R Donald Journal: BMC Infect Dis Date: 2007-11-29 Impact factor: 3.090
Authors: Eric W Hall; Sapna B Morris; Brittany K Moore; Linda Erasmus; Ronel Odendaal; Heather Menzies; Martie van der Walt; Sarah E Smith Journal: Pediatr Infect Dis J Date: 2017-12 Impact factor: 2.129
Authors: H J Zar; D P Moore; S Andronikou; A C Argent; T Avenant; C Cohen; R J Green; G Itzikowitz; P Jeena; R Masekela; M P Nicol; A Pillay; G Reubenson; S A Madhi Journal: Afr J Thorac Crit Care Med Date: 2020-10-13
Authors: Silvia S Chiang; Maria Dolynska; Natasha R Rybak; Andrea T Cruz; Omowunmi Aibana; Yana Sheremeta; Vasyl Petrenko; Andrii Mamotenko; Iana Terleieva; C Robert Horsburgh; Helen E Jenkins Journal: ERJ Open Res Date: 2020-09-14
Authors: Muhammad Osman; Elizabeth P Harausz; Anthony J Garcia-Prats; H Simon Schaaf; Brittany K Moore; Robert M Hicks; Jay Achar; Farhana Amanullah; Pennan Barry; Mercedes Becerra; Domnica I Chiotan; Peter C Drobac; Jennifer Flood; Jennifer Furin; Medea Gegia; Petros Isaakidis; Andrei Mariandyshev; Iveta Ozere; N Sarita Shah; Alena Skrahina; Elena Yablokova; James A Seddon; Anneke C Hesseling Journal: Emerg Infect Dis Date: 2019-03 Impact factor: 6.883
Authors: Habteyes Hailu Tola; Kourosh Holakouie-Naieni; Mohammad Ali Mansournia; Mehdi Yaseri; Ephrem Tesfaye; Zemedu Mahamed; Million Molla Sisay Journal: PLoS One Date: 2020-02-26 Impact factor: 3.240
Authors: Brittany K Moore; Linda Erasmus; Julia Ershova; Sarah E Smith; Norbert Ndjeka; Laura J Podewils Journal: PLoS One Date: 2020-04-07 Impact factor: 3.240
Authors: Elizabeth P Harausz; Anthony J Garcia-Prats; Stephanie Law; H Simon Schaaf; Tamara Kredo; James A Seddon; Dick Menzies; Anna Turkova; Jay Achar; Farhana Amanullah; Pennan Barry; Mercedes Becerra; Edward D Chan; Pei Chun Chan; Domnica Ioana Chiotan; Aldo Crossa; Peter C Drobac; Lee Fairlie; Dennis Falzon; Jennifer Flood; Medea Gegia; Robert M Hicks; Petros Isaakidis; S M Kadri; Beate Kampmann; Shabir A Madhi; Else Marais; Andrei Mariandyshev; Ana Méndez-Echevarría; Brittany Kathryn Moore; Parpieva Nargiza; Iveta Ozere; Nesri Padayatchi; Saleem- Ur-Rehman; Natasha Rybak; Begoña Santiago-Garcia; N Sarita Shah; Sangeeta Sharma; Tae Sun Shim; Alena Skrahina; Antoni Soriano-Arandes; Martin van den Boom; Marieke J van der Werf; Tjip S van der Werf; Bhanu Williams; Elena Yablokova; Jae-Joon Yim; Jennifer Furin; Anneke C Hesseling Journal: PLoS Med Date: 2018-07-11 Impact factor: 11.069